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hrombospondin (TSP)-1 has been reported to modulate
T cell behavior both positively and negatively. We
 
found that these opposing responses arise from inter-
actions of TSP1 with two different T cell receptors. The integrin
 
 
 
4
 
 
 
1 recognizes an LDVP sequence in the NH
 
2
 
-terminal
domain of TSP1 and was required for stimulation of T cell
adhesion, chemotaxis, and matrix metalloproteinase gene
expression by TSP1. Recognition of TSP1 by T cells depended
on the activation state of 
 
 
 
4
 
 
 
1 integrin, and TSP1 inhibited
interaction of activated 
 
 
 
4
 
 
 
1 integrin on T cells with its
counter receptor vascular cell adhesion molecule-1. The
 
 
 
4
 
 
 
1 integrin recognition site is conserved in TSP2. A
T
 
recombinant piece of TSP2 containing this sequence
replicated the 
 
 
 
4
 
 
 
1 integrin–dependent activities of TSP1.
The 
 
 
 
1 integrin recognition sites in TSP1, however, were
neither necessary nor sufﬁcient for inhibition of T cell
proliferation and T cell antigen receptor signaling by TSP1.
A second TSP1 receptor, CD47, was not required for some
stimulatory responses to TSP1 but played a signiﬁcant role
in its T cell antigen receptor antagonist and antiproliferative
activities. Modulating the relative expression or function of
these two TSP receptors could therefore alter the direction
or magnitude of T cell responses to TSPs.
 
Introduction
 
Thrombospondins (TSPs)* are a family of five extracellular
matrix proteins that have cell- and context-specific effects on
cell adhesion, growth, survival, differentiation, and motility
(for reviews see Adams et al., 1995; Roberts, 1996; Bornstein
et al., 2000; Lawler, 2000). TSP1 is the best-characterized
protein in this family, because it is readily purified from
platelet 
 
 
 
-granules. Mice lacking TSP1 are viable but have
several abnormalities, including a susceptibility to pneumonia
during the neonatal period (Lawler et al., 1998). Based on
the known role of the TSP1 receptor CD47 in immune
function (for review see Brown and Frazier, 2001) and the in
vitro responses to TSP1 of several cell types from the immune
system (Savill et al., 1992; Yabkowitz et al., 1993; Mansfield
and Suchard, 1994; Pierson et al., 1996; Vallejo et al., 2000;
Li et al., 2001), regulation of immune responses by TSP1
may contribute to this TSP1-null phenotype.
TSP1 influences cell behavior by interacting with
other extracellular matrix components, including latent
 
TGF
 
 
 
1, and with specific cell surface receptors. TSP1 re-
ceptors include 
 
 
 
v
 
 
 
3, 
 
 
 
4
 
 
 
1, 
 
 
 
5
 
 
 
1, and 
 
 
 
3
 
 
 
1 integrins;
CD36; CD47; low-density lipoprotein receptor–related
protein; and heparan sulfate proteoglycans (HSPGs) (Rob-
erts, 1996). Therefore, responses of cells to TSP1 proba-
bly reflect the integration of simultaneous signals from
multiple TSP1 receptors as well as receptors for some ex-
tracellular ligands of TSP1. The expression levels and acti-
vation states of these receptors must be considered to un-
derstand the function of each receptor in mediating
specific TSP1 responses.
Several TSP1 receptors are expressed in hematopoietic cells
and have been implicated in the regulation of immune func-
 
tions by TSP1. 
 
 
 
5
 
 
 
1 and 
 
 
 
4
 
 
 
1 integrins contributed to
 
PMA-stimulated adhesion of CD4
 
 
 
 peripheral T lymphocytes
on TSP1 (Yabkowitz et al., 1993). Based on global analysis of
gene expression in T cells exposed to TSP1, however, a
primary effect of TSP1 is to inhibit T cell antigen receptor
(TCR) signaling (Li et al., 2001). Studies using a T cell line
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demonstrated roles for CD47 and HSPGs in mediating the
inhibitory effects of TSP1 on T cell activation (Li et al.,
2001). TSP1 also inhibits T cell proliferation (Beppu et al.,
2001). Furthermore, a CD47-binding peptide from TSP1
inhibited the development of naive T cells into Th1 effec-
tors (Avice et al., 2000). In contrast, interactions of TSP1
or TSP1 peptides with HSPG and 
 
 
 
1 integrin receptors
stimulated Ras–MAP kinase signaling in T cells (Wilson et
al., 1999). Stimulatory effects of TSP1 or CD47-binding
peptides derived from TSP1 have also been reported for
the activation, infiltration, and clonal expansion of T cells
(Reinhold et al., 1997; Ticchioni et al., 1997, 2001;
Vallejo et al., 2000).
Taken together, these data indicate that TSP1 can both
stimulate and inhibit specific signal transduction pathways
in T cells. We have examined whether differential signaling
through specific T cell TSP1 receptors could reconcile
these apparently conflicting observations. We report here
that the TSP1 receptors CD47 and 
 
 
 
4
 
 
 
1 integrin are dif-
ferentially required for modulation of TCR signaling, T
cell proliferation, matrix metalloproteinase (MMP) expres-
sion, and T cell motility by TSP1. Furthermore, we dem-
onstrate that the 
 
 
 
4
 
 
 
1 integrin–dependent activities of
TSP1 are replicated by recombinant NH
 
2
 
-terminal por-
tions of TSP1 and TSP2 and identify peptide sequences in
the NH
 
2
 
-terminal regions of both TSPs that are recognized
by 
 
 
 
4
 
 
 
1 integrin.
 
Results
 
The NH
 
2
 
-terminal heparin-binding domains of TSP1 
and TSP2 contain an 
 
 
 
4
 
 
 
1 integrin recognition site
 
Although 
 
 
 
4
 
 
 
1 and 
 
 
 
5
 
 
 
1 integrins are known to mediate
adhesion of activated CD4
 
 
 
 T cells on a TSP1 substrate
(Yabkowitz et al., 1993), the sites in TSP1 recognized by
these integrins have not been defined. Recognition by 
 
 
 
5
 
 
 
1
integrin has been predicted to involve the RGD sequence at
residues 908–910, but no 
 
 
 
4
 
 
 
1 integrin binding site was
identified in TSP1. 
 
 
 
1 integrin–mediated adhesion of both
peripheral T cells (Yabkowitz et al., 1993) and Jurkat T lym-
phoma cells (Wilson et al., 1999) on TSP1 is activation de-
pendent. We therefore identified 
 
 
 
1 integrin binding sites
by comparing adhesion of unstimulated Jurkat cells and cells
treated with a 
 
 
 
1 integrin–activating antibody on recombi-
nant proteins spanning the entire TSP1 sequence (Fig. 1 A).
 
 
 
1 integrin–dependent adhesion was primarily mediated by
the NH
 
2
 
-terminal region of TSP1, with a minor activity co-
inciding with the RGD sequence in the last type 3 repeat.
Adhesion to a recombinant portion of TSP1 containing the
NH
 
2
 
-terminal 175 amino acids was completely inhibited by
a specific antagonist of 
 
 
 
4
 
 
 
1 integrin (Fig. 1 B). Adhesion
to recombinant proteins containing the type 3 repeats was
mediated by 
 
 
 
5
 
 
 
1 integrin, based on specific inhibition us-
ing both a specific function-blocking antibody and a peptide
antagonist selective for 
 
 
 
5
 
 
 
1 integrin (Fig. 1 B; unpub-
lished data). T cells generally do not express 
 
 
 
v integrins,
Figure 1.  4 1 and  5 1 integrins 
mediate Jurkat cell adhesion to TSP1. 
(A) Resting Jurkat cells (closed bars) or 
cells stimulated by the  1 integrin–
activating antibody TS2/16 (5  g/ml, 
gray bars) were incubated on substrates 
coated with TSP1, GST, or the indicated 
recombinant portions of TSP1 for 20 min 
at 37 C. Some TSP1 sequences were 
fused to the COOH terminus of GST (G) 
or T7 10B capsid protein (T). Trimeric 
TSP1 was coated at 20 nM on a subunit 
basis, trimeric 1–356 (NoC1) was coated 
at 100 nM, and the remaining fragments 
were coated at 600 nM. Cells attached/
mm
2 are presented as mean   SD, 
n   3. (B) Differential roles of  4 1 and 
 5 1 integrins in mediating adhesion to 
two sites in TSP1 and to TSP1 versus FN. 
Substrates coated with intact TSP1 (10 
 g/ml, solid bars), TSP1(1–175) (10  g/
ml, gray bars), GST–TSP1(877–1152) (30 
 g/ml, striped bars), or FN (10  g/ml, 
open bars) and blocked with BSA were 
incubated with TS2/16-activated Jurkat 
cells. Substrates blocked with BSA were 
used as a negative control. As indicated, 
cells were tested in the absence of 
inhibitors or in the presence of a specific 
 4 1 integrin antagonist ((4-((2- methylphenyl)aminocarbonyl)aminophenyl)acetyl-LDVP, 1  M) or the selective  5 1 integrin blocking peptide 
GRGDNP (300  M). Adhesion is presented normalized as a percent of the TS2/16-stimulated control for each substrate. (C) The NH2 termini 
of both TSP1 and TSP2 mediate activation-dependent T cell adhesion. Cell adhesion of resting Jurkat T cells (circles) or cells activated by TS2/16 
(triangles) or PMA stimulation (squares) on recombinant NH2-terminal trimeric portions of TSP1 (NoC1, closed symbols) or TSP2 (NoC2, open 
symbols) was determined by assay of hexosaminidase activity and is presented as mean   SD. (D)  4 1 integrin binding regions of TSP1 and 
TSP2 mediate adhesion of activated CD4
 T cells. Resting T cells (solid bars) and T cells activated in the presence of 10 ng/ml PMA (gray bars) 
were incubated on the indicated substrates for 15 min. Adhesion is presented as mean   SD, n   3. 
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and a specific antagonist of these integrins had no effect on
adhesion to intact TSP1 or recombinant fragments contain-
ing the RGD sequence (unpublished data). Based on flow
cytometry, we also confirmed that Jurkat cells lack 
 
 
 
3 1
(unpublished data), the other  1 integrin known to recog-
nize TSP1 (Krutzsch et al., 1999).
Because recombinant fragments of proteins may expose
cryptic binding sites for integrins that are not functional in
the intact proteins, we also compared the sensitivity to  4 1
and   5 1 antagonists of Jurkat cell adhesion on native
platelet TSP1 and plasma fibronectin (FN), a known ligand
for both integrins (Fig.1 B). Adhesion to TSP1 was more
sensitive to the  4 1 integrin antagonist and less sensitive to
the   5 1 antagonist than observed for adhesion of FN.
Therefore, both integrin binding sites are functional in im-
mobilized native TSP1, but Jurkat T cell adhesion to intact
TSP1 is preferentially mediated by  4 1 integrin.
Integrin-dependent adhesion of peripheral T cells to
TSP1 is induced by phorbol esters (Yabkowitz et al., 1993),
and we observed a similar induction of Jurkat cell adhesion
on trimeric human thrombospondin-1 residues 1–356
(NoC1) using PMA (Fig. 1 C). The dose dependence for
PMA-activated cells was similar to that for TS2/16-activated
cells. Remarkably, the corresponding recombinant trimeric
NH2-terminal region of TSP2 was even more active for pro-
moting adhesion of Jurkat cells activated using either PMA
or TS2/16 (Fig. 1 C). Therefore, the NH2-terminal regions
of both TSP1 and TSP2 contain binding sites for  1 inte-
grins.
Adhesion of CD4
  peripheral T cells showed a similar
preference for the  4 1 integrin binding sites in TSPs (Fig.
1 D). PMA activation stimulated adhesion to NoC1 and
thrombospondin-2 residues 1–359 (NoC2) to a similar ex-
tent as to TSP1, whereas adhesion to a fusion protein ex-
pressing the  5 1 integrin binding domain of TSP1 was
not enhanced by PMA.
Identification of an  4 1 integrin recognition 
sequence in TSP1 and TSP2
The smallest portion of TSP1 tested that supported  4 1
integrin–dependent adhesion of T cells contained amino
acid residues 1–175. Comparison of this sequence with
known  4 1 binding sequences in FN and vascular cell ad-
hesion molecule-1 (VCAM-1) (Vonderheide et al., 1994;
Moyano et al., 1997) using MACAW version 2.0.5 (Schuler
et al., 1991) identified a potential recognition site at residues
159–164, containing the sequence AELDVP. A synthetic
peptide with this sequence inhibited Jurkat cell adhesion on
substrates coated with NoC1 or NoC2 (Fig. 2 A). TSP2
contains a similar sequence at the same position (VALDEP)
that conserves the Asp residue typically required for  4 1
integrin ligands (Wang and Springer, 1998). A synthetic
peptide, VALDEP, inhibited adhesion on NoC1 and NoC2
(Fig. 2 A). Substitution of the Asp residue of this peptide
with Ala (VALAEP) markedly diminished its inhibitory ac-
tivity, indicating that this residue is important for binding of
the TSP2 peptide to  4 1 integrin. Adhesion to TSP1(1–
175) was also specifically inhibited by the TSP2 peptide
VALDEP but not by the control peptide VALAEP (Fig. 2
B). The  4 1 integrin specificity of T cell adhesion on
TSP1(1–175) and NoC1 was further confirmed using the
function-blocking  4 1 antibody P4C2 (Fig. 2 B).
To confirm the role of this sequence in  4 1 integrin–
mediated T cell adhesion on TSP1, Asp(162) of TSP1(1–175)
was mutated to an Ala residue, and adhesion was compared
using the native and mutant recombinant proteins (Fig. 2 C).
Activation-dependent adhesion was greatly diminished in the
mutant protein, although some residual  1-dependent adhe-
sion was observed in several independent experiments. There-
Figure 2. The NH2-terminal portions of both TSP1 and TSP1 
contain  4 1 integrin recognition sequences. (A) Identification of 
 4 1 binding sites in the NH2 termini of TSP1 and TSP2. T cell 
adhesion was determined by the colorimetric assay. The peptide 
acetyl-AELDVP was derived from NoC1, acetyl-VALDEP was 
derived from NoC2, and the control peptide acetyl-VALAEP 
substituted Ala for Asp in the proposed  4 1 integrin binding site. 
The  4 1 integrin antagonist (4-((2-methylphenyl)aminocarbo-
nyl)aminophenyl)acetyl-LDVP (phLDVP) was used as a positive 
blocking control. The solid bars represent adhesion on NoC1 
(30  g/ml) and the striped bars on NoC2 (30  g/ml). (B) TSP2 
peptide inhibits  4 1 integrin–dependent adhesion of Jurkat cells to 
NoC1 and TSP1(1–175). Substrates coated with 10  g/ml NoC1 
(solid bars) or TSP1(1–175) (striped bars) were incubated with 
resting or TS2/16-activated Jurkat cells or with activated cells in the 
presence of 150  M of TSP2 peptide acetyl-VALDEP, 150  M of the 
control peptide acetyl-VALAEP, or 5  g/ml of the  4 1 integrin 
function–blocking antibody P4C2. (C) Substrates coated with 6.2 
 g/ml of TSP1(1–175) or the mutated TSP1(1–175:D162A) were 
incubated with resting (solid bars) or TS2/16-stimulated Jurkat cells 
(striped bars). Cell adhesion was quantified microscopically.512 The Journal of Cell Biology | Volume 157, Number 3, 2002
fore, Asp(162) appears to play an important role in  4 1 in-
tegrin–mediated adhesion to this portion of TSP1, and the
heparin binding sites in TSP1(1–175) are not sufficient to
mediate adhesion of T cells. Residual activity of the mutant
protein is consistent with the weak inhibitory activity of the
peptide in which Asp was substituted by Ala (Fig. 2 A), but
we cannot exclude the possibility that additional sequences
participate in  4 1 integrin binding to this region of TSP1.
CD47 and HSPG are not sufficient to mediate T cell 
adhesion on TSP1
Although the preceding data establish that an  4 1 integrin
binding site is required for activation-dependent adhesion to
the NH2-terminal region of TSP1, they do not exclude roles of
the two additional T cell receptors, HSPG and CD47, in medi-
ating adhesion on intact TSP1. We therefore compared activa-
tion-dependent adhesion of Jurkat mutants deficient in  1 in-
tegrins (Romzek et al., 1998) or CD47 (Ticchioni et al., 2001).
Flow cytometry confirmed deficiencies in the respective TSP1
receptors without a significant loss of the complementary recep-
tor (Fig. 3 A). Neither the  1 integrin–activating antibody nor
PMA stimulation significantly stimulated adhesion of  1 inte-
grin–deficient T cells on intact TSP1 or its NH2-terminal re-
gion (Fig. 3 B). Therefore, the heparin and CD47 binding sites
of intact TSP1 were not sufficient to mediate adhesion in the
absence of  1 integrins. Conversely, adhesion of CD47-defi-
cient T cells to the three proteins was induced by the  1 inte-
grin–activating antibody and by PMA (Fig. 3 B). Although ad-
hesion of the CD47-deficient mutant was slightly less than that
of wild-type cells, the comparable decrease in adhesion to
TSP1, which contains the CD47 binding domain, and two re-
combinant portions of TSP1 lacking this domain indicates that
any contribution of CD47 to adhesion on TSP1 is indirect.
Recombinant portions of TSP1 and TSP2 inhibit 
binding of VCAM-1 to activated T cells
VCAM-1 is an important  4 1 integrin ligand for mediat-
ing leukocyte adhesion to endothelium at sites of inflamma-
Figure 3. CD47 is not required for activation-dependent T cell 
adhesion on TSP1. (A) Antibodies specific for  4 and  1 integrin 
subunits and CD47 were used for flow cytometry to compare 
expression of these TSP1 receptors in wild-type Jurkat cells and the 
 1-deficient (A1) and CD47-deficient mutant (JinB8). (B) Substrates 
coated with TSP1 (solid bars), NoC1 (striped bars), or TSP1(1–175) 
(open bars) were incubated with equal numbers of the indicated T 
cells alone or in the presence of 5  g/ml TS2/16 antibody or 10 ng/ml 
PMA. Cell adhesion is presented as mean   SD, n   3.
Figure 4. Thrombospondins compete with VCAM-1 for binding to 
 4 1 integrin. (A) NH2-terminal regions of TSP1 and TSP2 inhibit 
binding of soluble VCAM-1 to activated T cells. 
125I-labeled 
S7D–VCAM-1 was used as a probe to bind either resting or TS2/16- 
(0.5  g/ml) activated Jurkat T cells. NoC1 and NoC2 (10  g/ml) 
were used to antagonize the binding of 
125I-S7D–VCAM-1 (500,000 
cpm) to  4 1 integrin on T cells. The  4-specific antagonist (4-((2-
methylphenyl)aminocarbonyl)aminophenyl)acetyl-LDVP (phLDVP, 
1  M) was used as a positive control for  4 1 integrin blocking. 
S7D–VCAM-1 binding is presented as mean   SD, n   3. (B) Jurkat 
cell adhesion on wells coated using 1  g/ml S7D–VCAM-1 was 
determined using the colorimetric assay in the presence of the 
indicated concentrations of TSP1, 100  M of the TSP1 peptide 
acAELDVP, or 260 nM S7D–VCAM-1.Functional dissection of thrombospondin receptors | Li et al. 513
tion (Wang and Springer, 1998). Because VCAM-1 binds to
activated  4 1 integrin with high affinity (Jakubowski et
al., 1995), we used radiolabeled S7D–VCAM-1 to examine
whether NoC1 and NoC2 could competitively inhibit the
binding of VCAM-1 to T cells (Fig. 4 A). The specificity of
S7D–VCAM-1 binding in this assay was verified using the
 4 1 antagonist (4-((2-methylphenyl)aminocarbonyl)ami-
nophenyl)acetyl-LDVP (Lin et al., 1999), which inhibited
binding of S7D–VCAM-1 to both resting and activated T
cells. Both NoC1 and NoC2 inhibited S7D–VCAM-1
binding to the activated T cells (Fig. 4 A), confirming the
binding of both proteins to  4 1 integrin and suggesting
that both soluble TSP1 and TSP2 could antagonize  4 1/
VCAM-1–mediated adhesion.
To test this hypothesis, TSP1 was tested as an inhibitor of
Jurkat cell adhesion on immobilized S7D–VCAM-1 (Fig. 4
B). TSP1 was a dose-dependent inhibitor of adhesion on
immobilized VCAM-1, and the  4 1-binding peptide from
TSP1 also decreased T cell adhesion.
 4 1 integrin mediates chemotaxis of T cells to TSP1
A soluble form of VCAM-1 induced chemotaxis of Jurkat
and synovial T cells by binding to  4 1 integrin (Kitani et
al., 1998), suggesting that TSP1 might also be chemotactic
for these cells. TSP1 induced a biphasic concentration-
dependent chemotactic response in Jurkat cells that was
maximal at 30 nM (Fig. 5 A). NoC1 and NoC2 also stimu-
lated chemotaxis with similar dose response curves to plate-
let TSP1, indicating that the NH2-terminal region of TSP1
or TSP2 is sufficient to promote T cell chemotaxis. The
same region was sufficient to stimulate chemotaxis of human
primary CD4
  T cells, based on their responses to TSP1,
NoC1, and NoC2 (Fig. 5 B).
Based on inhibition by an  4 1 integrin function–block-
ing antibody (P4C2; Fig. 5 C),  4 1 integrin is necessary
for chemotaxis of Jurkat cells to TSP1, NoC1, and NoC2.
To confirm the requirement for  1 integrins, we compared
the chemotactic responses of wild-type and  1 integrin-defi-
cient Jurkat cells (Fig. 5 D). The  1 integrin-deficient cells
failed to migrate to TSP1 or the recombinant proteins, but
migration to the CXCR4-binding chemokine SDF1  was
normal in the  1 integrin–deficient cells. Although these
cells could migrate in a chemotaxis assay without expressing
 1 integrins, the NH2-terminal heparin-binding activities of
NoC1 and NoC2 were not sufficient to promote chemotaxis
in the absence of integrins.
We could not directly evaluate the role of CD47 in TSP1-
stimulated chemotaxis using this approach, because CD47-
deficient JinB8 cells did not migrate to any attractant tested
(unpublished data). However, a function-blocking CD47
antibody (B6H12) inhibited motility stimulated by intact
TSP1, NoC1, or NoC2 (Fig. 5 D). The latter do not con-
tain the known TSP CD47 binding site, indicating that
CD47 plays an essential but indirect role in these  4 1-medi-
ated chemotactic responses.
Figure 5.  4 1 integrin mediates chemotaxis of T cells to TSP1. 
(A) A modified Boyden chamber assay using polylysine-coated
filters to support integrin-independent adhesion was used to charac-
terize Jurkat T cell chemotaxis. The chemokine SDF1-  (25 ng/ml) 
was used as positive control (744 cells migrated/field). Results are 
represented as migrated cells per 20  field, mean   SD, for the 
indicated concentrations of TSP1 (closed circles), NoC1 (open 
circles), and NoC2 (open triangles). (B) Chemotaxis of CD4
  T cells 
to optimal concentrations of TSP1, NoC1, and NoC2. (C) Cell 
migration assays stimulated by 30  g/ml TSP1, 20  g/ml NoC1, or 
20  g/ml NoC2 were performed in the presence or absence of an 
 4 1 integrin–specific blocking antibody (P4C2, 5  g/ml) mixed 
with cells in the upper chamber. (D, left)  4 1 integrin is necessary 
for chemotaxis to NoC1 and NoC2 but not for chemotaxis to the 
chemokine SDF1. Chemotaxis of the  1-deficient Jurkat-derived A1 
to TSP1 (20  g/ml), NoC1 (5  g/ml), and NoC2 (5  g/ml) was 
assessed as described above. The chemokine SDF1-  was used as 
a positive control to confirm the migration capacity of the A1 cell 
line. (D, right) The CD47 function–blocking antibody B6H12 
(20  g/ml) added to the upper well with Jurkat cells inhibited 
chemotaxis stimulated by TSP1 as well as by NoC1 and NoC2, 
which lack the CD47 binding site.514 The Journal of Cell Biology | Volume 157, Number 3, 2002
TSP1 induces MMP expression through 
 4 1 integrin binding
Two previously known  4 1 integrin ligands, VCAM-1 and
FN, induce MMP-2 and MMP-9 mRNA and protein expres-
sion in T cells (Esparza et al., 1999; Yakubenko et al., 2000).
TSP1 also induces MMP-9 in endothelial cells, but this in-
duction was attributed to a different TSP1 receptor (Qian et
al., 1997). We used reverse transcriptase (RT)-PCR to exam-
ine expression of mRNAs for several MMPs in Jurkat cells ex-
posed to soluble or immobilized TSP1 (Fig. 6 A). Both forms
of TSP1 induced MMP-2, but the response was greater using
immobilized TSP1. Therefore, all subsequent experiments
were performed using immobilized proteins. NoC1 and
NoC2 also induced MMP-2 expression. The responses were
time dependent and maximal for both proteins at 4 h (Fig. 6
A). Similar results were observed using CD4
  T cells (Fig. 6
A). Both immobilized and soluble TSP1 induced MMP-2
mRNA, and induction was also observed using NoC2.
MMP-2 induction by intact TSP1 and the NoC constructs
were  1 integrin–mediated, because no significant induction
of MMP-2 mRNA was observed using  1 integrin–deficient T
cells (Fig. 6 B). CD47 may play an indirect role in this re-
sponse, because TSP1 did not induce MMP2 mRNA in
CD47-deficient T cells, and the NoC fragments, which lack
the CD47 binding site, were also inactive (Fig. 6 B). TSP1,
NoC1, and NoC2 also induced mRNA expression of MMP-9
and MMP-7 (Fig. 6 C). In contrast, no induction was observed
of the membrane-bound MMP-2 activator MMP-14 (Fig. 6
C), which was previously shown to be induced by FN (Esparza
et al., 1999). These data indicate that the NH2-terminal re-
gions of TSP1 and TSP2, which contain the  4 1 integrin
binding sites, are sufficient to induce expression of MMP-2,
MMP-7, and MMP-9 mRNAs in T cells, and CD47 may be
indirectly required for the MMP-2 response to TSP1.
MMP induction at the protein level was confirmed by gel-
atin zymography (Fig. 6 D). TSP1, NoC1, and NoC2 in-
creased MMP-9 activity. MMP-2 activity was induced by
Figure 6. TSP1 and TSP2 induce MMP expression in T cells via 
 4 1 integrin binding. (A) Total mRNA was prepared from Jurkat 
cells (top) incubated for the indicated times on substrates coated 
with 10  g/ml NoC1 or NoC2 or for 2 h with 20  g/ml TSP1
immobilized (I) or in solution (S). Primary CD4
  T cells (bottom) 
were treated for 4 h in the presence of 1 mM Mn
2  as indicated. 
RT-PCR products using GAPDH or MMP-2 primers and a control 
reaction without reverse transcriptase ( RT) were analyzed after 31 
(Jurkat) or 33 cycles of amplification (CD4
  cells) using a 1.5% 
agarose gel stained with ethidium bromide. (B) MMP-2 mRNA was 
analyzed using wild-type,  1-deficient, or CD47-deficient Jurkat 
cells after 4 h treatment with the indicated immobilized proteins. (C) 
Total mRNAs from Jurkat cells incubated for 4 h on uncoated plates 
or plates coated with 10  g/ml NoC1, 10  g/ml NoC2, or 20  g/ml 
TSP1 were analyzed using the indicated primer sets (24 cycles for 
MMP-9 and 34 cycles for MMP-7 and MMP-14). (D) Gelatinase 
activity was assessed by zymography using 24 h–conditioned media 
from Jurkat cells plated on dishes coated with BSA, 10  g/ml NoC1 
or NoC2, or 30  g/ml TSP1.
Figure 7.  1 integrins are not required for the inhibitory effect of 
TSP1 on TCR-mediated T cell activation. (A) The  4 1 integrin and 
NH2-terminal heparin binding sites of TSP1 and TSP2 are not sufficient 
to inhibit TCR-mediated T cell activation. Jurkat T cells with or with-
out TCR stimulation by surface-bound anti-CD3 antibody, were 
treated with TSP1 (30  g/ml), NoC1 (30  g/ml), or NoC2 (30  g/ml). 
Cells were stained with phycoerythrin-conjugated anti-CD69 anti-
body to measure T cell activation and analyzed by flow cytometry. 
(B)  1 integrins are not required for inhibition of TCR-mediated 
T cell activation by TSP1. The wild-type Jurkat cells and  1-
deficient A1 cells were stimulated using surface-bound anti-CD3 
antibody with or without TSP1. Cell surface CD69 was analyzed by 
flow cytometry as in panel A.Functional dissection of thrombospondin receptors | Li et al. 515
NoC2 and, apparently, was processed to a smaller activated
form in cells exposed to TSP1 (Fig. 6 D).
 4 1 integrin binding is not sufficient for inhibition 
of TCR signaling by TSP1
We previously demonstrated that TSP1 inhibits TCR-medi-
ated T cell activation (Li et al., 2001). To determine
whether  4 1 integrin is involved in this activity, we tested
NoC1 and NoC2 for inhibition of TCR-mediated T cell ac-
tivation (Fig. 7 A). TSP1 inhibited TCR-mediated T cell ac-
tivation measured by induction of cell surface CD69 expres-
sion (90% inhibition in mean fluorescent intensity relative
to the anti-CD3–stimulated positive control), but NoC1
(6% inhibition) and NoC2 ( 12% inhibition) showed
minimal or no inhibitory effects even using a fourfold higher
molar concentration. Thus, the NH2-terminal regions of
these proteins are not sufficient to mediate the inhibitory ac-
tivity of TSP1 for T cell activation. TSP1 comparably inhib-
ited CD69 expression in the wild-type and  1 integrin–defi-
cient Jurkat cell lines (Fig. 7 B), demonstrating that  1
integrins are not required for the inhibitory effect of TSP1
on TCR signaling. Therefore binding of TSP1 to  4 1 in-
tegrin is neither necessary nor sufficient for the antagonist
activity of TSP1 on TCR signaling. We previously demon-
strated that two other T cell receptors for TSP1, CD47 and
HSPG, mediate this inhibitory activity (Li et al., 2001).
The antiproliferative activity of TSP1 requires CD47 
but not  4 1 integrin
As recently reported for in vitro cocultures of peripheral T
cells with antigen-presenting cells (Beppu et al., 2001), solu-
ble TSP1 was a dose-dependent inhibitor of Jurkat T cell
proliferation (Fig. 8 A). In contrast, soluble NoC1 had no
effect on proliferation (Fig. 8 A), indicating that the  4 1
integrin and heparin binding sites contained in this trimeric
portion of TSP1 are not sufficient to mediate its antiprolif-
erative activity. Furthermore, immobilized TSP1 or NoC1
did not significantly inhibit proliferation after coating at the
same concentrations (unpublished data), indicating that in-
hibition of T cell proliferation is a specific function of solu-
ble TSP1. To further examine whether  4 1 integrin is nec-
essary for the antiproliferative activity of intact TSP1, we
used  1 integrin–deficient Jurkat cells. Soluble TSP1 inhib-
ited proliferation of the  1-deficient T cells with a similar
dose response as that obtained using the wild-type cells (Fig.
8 B). As expected, NoC1 did not inhibit proliferation of the
 1-deficient cells. In contrast, proliferation of the CD47-
deficient Jurkat mutant was only weakly inhibited by TSP1
(23% inhibition at 40  g/ml; Fig. 8 C). The weak inhibi-
tion appeared to be specific, inasmuch as intact TSP1 was
significantly more inhibitory than the NoC1 portion of
TSP1. Nevertheless, these data demonstrate that CD47 ex-
pression on the T cells is necessary for the full antiprolifera-
tive activity of soluble TSP1.
Discussion
Our results demonstrate that interactions of TSP1 with two
of its receptors on T cells elicit different biological responses.
A sequence in the NH2-terminal pentraxin modules of
TSP1 and TSP2 binds to  4 1 integrin and stimulates che-
motaxis, MMP gene expression, and activation-dependent
adhesion of T cells. The NH2-terminal heparin binding sites
may contribute to some of these activities but are not suffi-
cient, based on integrin blocking studies, mutagenesis of the
integrin binding sequence, and loss of activity in  1 inte-
grin–deficient Jurkat cells. These activities of TSP1 are re-
tained in a recombinant portion of TSP1 that lacks binding
sites for  5 1 integrin, CD36, and CD47. Therefore, inter-
actions of TSP1 with the latter receptors are not required for
these biological activities, although CD47 expression ap-
pears to play an indirect role in T cell chemotaxis and MMP
induction. In contrast, the same recombinant proteins failed
to replicate the antiproliferative and TCR antagonist activi-
ties of TSP1. These activities are mediated, at least in part,
by interactions of TSP1 with CD47 and HSPGs on T cells
(this study; Li et al., 2001).
Cellular responses to TSP1 can be modulated by altering
the expression of specific TSP1 receptors, the activation
Figure 8. The antiproliferative activity of TSP1 for T cells requires 
CD47 but not  1 integrin expression. Wild-type Jurkat cells (A) and 
 1 integrin– (B) and CD47-deficient clones (C) were grown for 72 h 
in the presence of the indicated concentrations of TSP1 (closed 
circles) or NoC1 (open circles). Net proliferation was assessed from 
colorimetric tetrazolium assays at times 0 and 72 h. Results are 
presented as mean   SD, n   3, normalized to the proliferation
response of untreated cells for each cell line.516 The Journal of Cell Biology | Volume 157, Number 3, 2002
state of these receptors, or conformation states of TSP1 that
regulate its binding to specific receptors (Rodrigues et al.,
2001). T cells express at least three TSP1 receptors, and of
these,  4 1 is known to be regulated in its affinity and
avidity for binding to ligands.  4 1 integrin is inactive in
resting T cells but has low activity in resting Jurkat cells
(Jakubowski et al., 1995). Activation of protein kinase C by
phorbol esters, which increases  4 1 avidity but not its af-
finity for ligands (for review see Woods and Shimizu,
2001), induced adhesion of T cells on immobilized TSP1
and the NH2-terminal region of TSP2. Soluble TSP1 also
inhibited interactions of activated  4 1 integrin with its
high-affinity ligand VCAM-1. Therefore both stimulatory
and inhibitory activities of TSPs may be modulated by sig-
nals that alter  4 1 integrin activation.  4 1 integrin acti-
vation is modulated by signals resulting from ligation of the
TCR (Jakubowski et al., 1995), CD47 (Ticchioni et al.,
2001), and some chemokine receptors (Jakubowski et al.,
1995). Notably, CD47 itself is a TSP1 receptor, and bind-
ing of TSP1 peptides to CD47 activates several integrins
(for review see Brown and Frazier, 2001). Therefore, bind-
ing of soluble TSP1 to CD47 could potentially enhance ad-
hesion of T cells to immobilized TSP1 mediated by  4 1
integrin. This cross-talk between CD47 and  4 1 integrin
may regulate arrest of T cells on inflammatory endothelium
(Ticchioni et al., 2001).
Our data define a new  4 1 integrin recognition sequence
in the NH2-terminal pentraxin-related domain of TSP1. This
site is conserved in TSP2 and is distinct from the previously
identified  3 1 integrin binding site in the same domain of
TSP1 (Krutzsch et al., 1999). Thus, the NH2-terminal do-
mains of TSPs functionally resemble the paralogous G do-
mains of laminins (Beckmann et al., 1998) in that they con-
tain multiple  1 integrin recognition sites. Although the
LDVP sequence we identified in TSP1 is conserved at the cor-
responding position in some laminin G domain modules (un-
published data), recognition of laminins by  4 1 integrin has
not been reported. Based on alignment with other members
of the pentraxin family of known structure (Beckmann et al.,
1998), the  4 1 integrin binding sites of TSP1 and TSP2 are
located in a loop connecting the predicted   strands J and K.
This is consistent with the location of the  4 1 integrin bind-
ing sequence IDSP of VCAM-1 in a loop between its C and
D   strands (Jones et al., 1995).
TSP1 regulates the expression of MMP-9 in endothelial
cells (Qian et al., 1997), and TSP2 also regulates extracellu-
lar MMP-2 through direct interactions (Yang et al., 2001).
Previously identified ligands of  4 1 integrin, including
VCAM1 and FN, induced expression of MMPs in T cells
and fibroblasts (Huhtala et al., 1995; Xia et al., 1996b;
Yakubenko et al., 2000). Our data demonstrate that recom-
binant portions of TSP1 and TSP2 containing  4 1 inte-
grin binding sites are sufficient to induce MMP-2, MMP-7,
and MMP-9 expression in T cells. Notably, these recombi-
nant proteins lack the TSP type 1 repeat sequence impli-
cated in MMP-9 induction by TSP1 in endothelial cells
(Qian et al., 1997). Our data suggest that MMP induction is
a general T cell response to all  4 1 integrin ligands and
that this integrin may mediate the observed effects of TSPs
on MMP expression in other cell types.
Inhibition of TCR signaling by TSP1 in Jurkat cells is in-
dependent of  4 1 integrin ligation, but this result does not
eliminate the possibility that TSP1 and TSP2 may positively
modulate T cell activation through this receptor. Integrins
are well-documented costimulators of TCR signaling in pe-
ripheral T cells (for review see Epler et al., 2000). However,
Jurkat cells lack CasL, which is required for  1 integrin co-
stimulation of TCR signaling (Kamiguchi et al., 1999).
Therefore, we can observe only an inhibitory effect of TSP1
on TCR signaling in Jurkat T cells. In normal T cells, a sec-
ond positive signal from TSP1 interacting with  4 1 inte-
grin may offset this inhibition. Further investigation is
needed to define the net effect of TSP1 on TCR signaling
and T cell activation in various physiological and pathologi-
cal contexts.
Both TSP1 and FN recognize  4 1 and  5 1 integrins
on T cells. Our data show that the relative contributions of
these two integrins differ, however, for mediating T cell ad-
hesion to each protein.  5 1 integrin is the predominant
FN receptor, whereas  4 1 is the major TSP1 receptor. FN
is a constitutive component of extracellular matrix, but in
most tissues TSP1 is only present in matrix at sites of injury
and tissue remodeling (Adams et al., 1995). The different
relative strengths of TSP1 and FN interactions with these
two integrins may therefore indicate to a T cell whether the
tissue microenvironment it transverses is undergoing these
processes, and this may in turn modulate each of the T cell
behaviors we have examined here.
Although FN and TSP1 share these two integrin receptors
on T cells, their effects on T cell behavior differ. FN stimu-
lates proliferation of T cells and TCR signaling (Davis et al.,
1990; Shimizu et al., 1990), whereas TSP1 inhibits these re-
sponses.  4 1 and  5 1 were implicated in the stimulation
of T cell proliferation by FN (Davis et al., 1990; Shimizu et
al., 1990), which is consistent with our evidence that these
integrins mediate some positive effects of TSP1 on T cells
but not its antiproliferative activity. CD47, which is re-
quired for the inhibitory activities, is a receptor for TSP1
but not for FN.
Our data suggest that TSP1 and TSP2 could modulate re-
circulation of T cells and diapedesis of other leukocytes. We
demonstrated that TSPs inhibit VCAM-1 binding to T cells
and T cell adhesion mediated by  4 1 integrin binding to
VCAM-1. Because  4 integrin function is essential for lym-
phocyte recruitment to sites of inflammation (Arroyo et al.,
2000), TSP1 and TSP2 could potentially inhibit this process.
Conversely, we found that TSP1 and the NH2-terminal por-
tion of TSP2 stimulate chemotaxis of T cells by engagement of
the same integrin and stimulate expression of several MMPs
that may be necessary for passage of T cells through basement
membranes (Xia et al., 1996a; Faveeuw et al., 2001) or tissue
invasion (Lynch and McDonnell, 2000). Thus, expression of
TSP1 or TSP2 in tissues could enhance recruitment of T cells
to these sites by facilitating cell motility and invasion. Com-
bined with the higher potency we observed for stimulating
chemotaxis versus inhibiting  4 1 integrin–VCAM-1 bind-
ing, the net effect of TSP1 and TSP2 expression in tissue may
be to enhance recruitment. In this context, it is notable that
increased leukocyte recruitment was observed in breast tumors
overexpressing TSP1 (Weinstat-Saslow et al., 1994).Functional dissection of thrombospondin receptors | Li et al. 517
Materials and methods
Proteins and peptides
TSP1 was purified from human platelets obtained from the NIH blood
bank (Roberts et al., 1994). A recombinant trimeric portion of TSP1 (NoC1,
residues 1–356 of the mature protein) was prepared as previously de-
scribed in insect cells using the pAcGP67.coco transplacement plasmid to
generate recombinant baculovirus (Misenheimer et al., 2000). The corre-
sponding recombinant portion of TSP2 (NoC2, residues 1–359 of the ma-
ture protein; GenBank/EMBL/DDBJ accession no. L12350) was expressed
and purified by a similar method using pAcGP67.coco and was also tri-
meric. The sequence of NoC2 at residues 153–155 is DSF rather than GPV
as reported in GenBank/EMBL/DDBJ. MG63 human osteosarcoma cells
were the source of the 5  portion of the full-length TSP2 cDNA used in pre-
paring pAcGP67.coco for the expression of recombinant NoC2. A recom-
binant piece of TSP1 (Met residues 1–175; provided by Tikva Vogel, Bio-
Technology General, Rehovot, Israel), a T7 10B capsid protein fusion
expressing residues 879–947 (Guo et al., 1998), and glutathione-S-trans-
ferase (GST) fusion proteins expressing various regions of TSP1 (provided
by Jack Lawler, Harvard University, Boston, MA) were prepared as previ-
ously described (Vogel et al., 1993; Guo et al., 1998). Synthetic peptides
derived from TSP1 and TSP2 were synthesized and characterized as previ-
ously described (Krutzsch et al., 1999).
Recombinant soluble 7 domain VCAM-1 (S7D–VCAM-1, residues 1–674
of the mature protein; GenBank/EMBL/DDBJ accession no. X53051) was
expressed in insect cells after insertion into pAcGP67.coco and generation
of recombinant baculovirus. S7D–VCAM-1 was purified on a Ni
 -chelate
resin as previously described for NoC1 (Misenheimer et al., 2000).
Site-directed mutagenesis of Asp(162) to Ala in TSP1(1–175) was per-
formed using the Stratagene QuickChange mutagenesis kit. The forward
and reverse primer sequences were 5 -GAG AAT GCT GAG TTG GCC
GTC CCC ATC CAA AGC G-3  and 5 -GCT TTG GAT GGG GAC GGC
CAA CTC AGC ATT CTC C-3 , respectively. After transformation into
Escherichia coli XL1- blue, mutant clones were verified by DNA sequenc-
ing. The mutated plasmid was then transformed into E. coli A4255F
 .
E. coli A4255F
  transformants were grown overnight at 28 C in Superbroth
plus 50  g/ml carbenicillin and induced by adding 10 g/liter of glucose
and incubating at 42 C for 2 h. Inclusion bodies were isolated, and the
mutant recombinant protein was purified as previously described for the
wild-type recombinant protein (Vogel et al., 1993).
Cell culture
Jurkat T cells were maintained in RPMI 1640 medium supplemented with
10% FBS, 2 mM glutamine, penicillin, and streptomycin.  1 integrin–defi-
cient (A1) and CD47-deficient (JinB8) T cell lines derived from Jurkat T
cells (Romzek et al., 1998; Ticchioni et al., 2001) were provided by Yoji
Shimizu (University of Minnesota Medical School, Minneapolis, MN) and
Eric Brown (University of California San Francisco, San Francisco, CA), re-
spectively. All cell cultures were grown at 37 C with 5% CO2.
Human primary CD4
  T cells were isolated by magnetic sorting using
CD4 positive selection MicroBeads and autoMACS magnetic isolation sys-
tem (Miltenyi Biotec). Human peripheral blood mononuclear cells were
isolated by Ficoll gradient centrifugation from buffy coats obtained from
normal donors (protocol no. 99-CC-0168), and CD4
  cells were purified
according to the manufacturer’s instructions. Cells were resuspended in
complete RPMI medium and rested at 4 C overnight. FACS
® analysis dem-
onstrated  95% purity of the isolated CD4
  T cells (unpublished data).
Antibodies and reagents
Anti-CD3 antibody (clone HIT3a) was obtained from BD PharMingen.
Anti-CD47 antibody (clone C1Km) was from ICN Biomedicals. A function-
blocking antibody for  4 1 integrin (clone P4C2) was from GIBCO BRL. A
CD47 function–blocking antibody, B6H12, and the  1 integrin function–
stimulating antibody, TS2/16 (Hemler et al., 1984), were produced from
hybridoma cell lines (American Type Culture Collection). A human inte-
grin  1 blocking antibody (mAb13) was provided by Ken Yamada (Na-
tional Institute of Dental and Craniofacial Research, Bethesda, MD). An
 5 1 integrin peptide antagonist (GRGDNP; Pierschbacher and Ruoslahti,
1987) and an  4 1 integrin antagonist (4-((2-methylphenyl)aminocarbo-
nyl)aminophenyl)acetyl-LDVP (Lin et al., 1999) were obtained from
Bachem. SDF1  was obtained from Sigma-Aldrich.
Cell adhesion assays
Matrix protein–mediated cell adhesion was measured as previously de-
scribed (Wilson et al., 1999). TSP1 and the NoC proteins were coated in
PBS, and the other recombinant portions of TSP1 were coated in 25 mM
NaHCO3 buffer, pH 8.2. Overnight cell cultures ( 5   10
5 cells/ml) were
resuspended in RPMI with 0.1% BSA (Sigma-Aldrich) at 2   10
5 cells/ml.
The plates were chilled in a 4 C bath, and 100  l of cell suspension with
the indicated treatment was added into each well. The plates were then in-
cubated in a 37 C bath for 15 min. Unbound cells were removed by wash-
ing, and adherent cells were quantified by hexosaminidase assay (Wilson
et al., 1999).
Adhesion was also assessed using a microscopic assay. TSP1, recom-
binant proteins, or S7D–VCAM-1 diluted in Dulbecco’s PBS or NaHCO3
buffer were adsorbed on bacteriological polystyrene dishes by incuba-
tion overnight at 4 C. After blocking with 1% BSA in Dulbecco’s PBS, ad-
hesion assays were performed by adding cells to prewarmed dishes con-
taining RPMI with 1 mg/ml BSA. Cell attachment and spreading were
quantified after 15 min by washing to remove nonadherent cells, fixing
the adherent cells with 1% glutaraldehyde in PBS, and staining with Diff-
Quik (Dade International).
Cell migration assay
A 48-well microwell modified Boyden chamber was used with 8- m (Jur-
kat) or 5- m (CD4
  T cells) pore polyvinylpyrrolidone-free polycarbonate
membranes (Neuro Probe, Inc.). Wells in the lower chamber contained as-
say medium (RPMI with 0.1% BSA) and attractants as indicated. Polycar-
bonate membranes were coated overnight at 4 C with either 100  g/ml of
gelatin in 0.1% acetic acid or 20  g/ml of polylysine in PBS and air dried.
Jurkat cultures ( 5   10
5 cells/ml) were resuspended in assay medium at
2   10
6 cells/ml with the indicated additions, added into wells of the up-
per chamber, and incubated at 37 C for 2–5 h. The membranes were fixed
and stained, cells on the upper face were removed, and cells migrated to
the lower face of the membrane were counted microscopically.
Flow cytometry analysis
To analyze T cell activation, expression of CD69 was measured by flow
cytometry as previously described (Li et al., 2001). Cells were activated by
incubating with surface-bound anti-CD3 antibody (BD PharMingen) in
RPMI plus 0.1% BSA. After a 24-h stimulation at 37 C, the cells were
washed and stained with PE-conjugated anti-CD69 antibody (BD PharMin-
gen). CD69 expression was quantified using a FACS
®Caliber flow cytome-
ter (Becton Dickinson).
Table I. Primer sequences for MMPs
MMP Primer sequences PCR product size
MMP-2
sense 5 CCTGAGCTCCCGGAAAAGATTGAT3 
antisense 5 AGCAGCCTAGCCAGTCGGATTTGA3  442 bp
MMP-7
sense 5 CGGAATTCCACCTACAGGATCGTATCATA3 
antisense 5’GCTCTAGATCAGAGGAATGTCCCATACCC3’ 353 bp
MMP-9
sense 5 AGTTCCCGGAGTGAGTTGAA3 
antisense 5 CTCCACTCCTCCCTTTCCTC3  196 bp
MMP-14
sense 5 AAACCCCAAAAACCCCACCTATG3 
antisense 5 GGCGTCTGAAGAAGAAGACTGCAAG3  773 bp518 The Journal of Cell Biology | Volume 157, Number 3, 2002
VCAM-1 cell binding assay
S7D–VCAM-1 was labeled with 
125I using Iodogen (Pierce Chemical Co.).
Jurkat T cells were washed with 4 C chilled Dulbecco’s PBS (without Ca
2 
or Mg
2 ) and resuspended in chilled binding buffer (RPMI with 0.1% BSA)
at 3   10
6 cells/ml. On ice, 100  l of the cell suspension was premixed
with the indicated concentrations of TSP1, NoC1, or NoC2. 
125I-S7D–
VCAM-1, diluted in chilled binding buffer, was added into each tube to
bring the final volume to 200  l. The tubes were mixed by vortexing and
transferred to a 37 C water bath for 15 min. The cell suspensions were
then transferred to plastic tubes containing 100  l of Nyosil oil (William F.
Nye, Inc.), centrifuged for 1 min, and washed with 200  l of cell binding
buffer. The pellets were collected, and the bound radioactivity was quanti-
fied.
Proliferation
Effects of soluble or immobilized TSP1 reagents on Jurkat cell proliferation
were quantified using a tetrazolium dye proliferation assay (Cell Titer As-
say; Promega). The indicated cell lines (7.5   10
3 cells/well) were seeded
in 96-well Nunc tissue culture plates for treatment with soluble proteins or
in 96-well Nunc Maxisorp plates precoated with TSP1 or NoC1 and
blocked with 1% BSA. Proliferation was assessed after growth for 72 h in
RPMI medium containing 2% FCS.
MMP expression
Semiquantitative RT-PCR was used to analyze effects of TSPs on expres-
sion of mRNAs for MMP-2, MMP-7, MMP-9, and MMP-14 by Jurkat and
CD4
  T cells. Cells were placed in untreated Falcon 1008 dishes or dishes
previously coated overnight with TSP1, NoC1, or NoC2. Total RNA was
isolated using Trizol reagent (GIBCO BRL) according to the instructions of
the manufacturer. First strand cDNA synthesis was performed with Super-
script II reverse transcriptase (GIBCO BRL) and 16  g/ml oligo(dT) using 2
 g of total RNA. The enzyme was inactivated at 70 C for 15 min. The
cDNA was amplified using Platinum Taq DNA polymerase (GIBCO BRL)
and specific primer pairs to amplify glyceraldehyde phosphate dehydroge-
nase, MMP-2, MMP-7, MMP-9, or MMP-14 sequences (Table I). Amplifi-
cation was conducted using two cycles of 1 min at 95 C and 4 min at 55 C
followed by the indicated number of cycles of 1 min at 95 C, 2.5 min at
55 C, and 10 min at 70 C.
For gelatin zymography (Yakubenko et al., 2000), 0.02% Brij 35 was
added to 24 h serum-free conditioned media, which were then concen-
trated 50- to 100-fold using Centricon YM10. Samples were analyzed us-
ing 10% acrylamide, 0.1% gelatin SDS gels without reduction. Gels were
washed and developed for 24 h at room temperature in 50 mM Tris, 200
mM NaCl, 5 mM CaCl2, 0.05% Tween 20, 0.02% NaN3, pH 7.2.
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